Cite
HARVARD Citation
Paz-Ares, L. et al. (2021). First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet oncology. 22 (2), pp. 198-211. [Online].